Green Biologics Appoints Jim Hohman to its Board of Directors
4th February 2015
Green Biologics Appoints Jim Hohman to its Board of Directors Chemical Industry Executive to Play Key Non-Executive Role
Chemical Industry Executive to Play Key Non-Executive Role
Gahanna, Ohio and Abingdon, Oxfordshire U.K. (February 4, 2015) – Green Biologics (GBL) announced today the appointment of James J. Hohman to a non-executive director position on their board of directors. Hohman was formerly President of OMNOVA Solutions’ Performance Chemicals business unit and a corporate Senior Vice President of OMNOVA.
Prior to GenCorp/OMNOVA, Mr. Hohman held key general management, business and marketing management positions with BP Chemicals and B.F. Goodrich.
“Jim is a seasoned leader and executive in the chemicals industry and we are excited to welcome him to Green Biologics’ board of directors,” said Sean Sutcliffe, Green Biologics’ CEO. “We believe his strong experience in growth, both through acquisitions and through organic growth, as well as his global experience, will be extremely valuable as Green Biologics emerges as a leader in renewable chemicals.”
“We conducted an exhaustive search for someone who would further strengthen our board’s breadth of talent and background, and we are delighted to have identified such an outstanding and experienced leader,” said Simon Mansfield, Chairman of Green Biologics’ board. “I am confident Jim will make an important and positive impact on our board.”
In his 19 years at OMNOVA and GenCorp, Mr. Hohman was instrumental in broadening the company’s global reach in emulsion polymers and specialty chemicals to include applications around the world in oil and gas, construction, high performance coatings, nonwovens, adhesives, automotive, polymer and rubber modification, antioxidants, coated paper and packaging, carpet and flooring, and many others.
At OMNOVA/GenCorp, Mr. Hohman led negotiations for a number of key acquisitions including the Goodyear/Calhoun, Georgia latex facility, the U.S. specialty chemicals businesses of Sequa Chemicals and PolymerLatex, and the acquisition of ELIOKEM, a key acquisition that significantly broadened OMNOVA’s served markets and expanded the company’s global manufacturing footprint.
“I admire Green Biologics for their vision in building a leading renewable chemicals company, and for the aggressive and pragmatic approach they’ve taken to production scale-up and commercialization,” said Mr. Hohman. “In getting to know the company I have developed tremendous respect for the board members and management team, in both what they have done and their clear plans for the future, and I look forward to helping them realize their vision.”
Mr. Hohman earned his bachelor’s degree in Honors Chemistry from The Ohio State University and his MBA from the University of Louisville. He joined the board of directors of Pilot Chemical Company on January 14, 2015. Most recently, he was a member of the Strategic Review Executive Taskforce of the American Chemistry Council, a former member of both the Corporate Visiting Committee of Case Western Reserve University in Cleveland, Ohio and the Advisory Board of The Ohio State University’s College of Math and Physical Sciences, and from 2002 to 2010 was a founding board member of RohmNova, a joint venture between OMNOVA and Rohm & Haas Corp.
About Green Biologics
Green Biologics Ltd (GBL) is a renewable chemicals company based in Abingdon, England with a wholly owned U.S. operating company, Green Biologics Inc., based in Gahanna, Ohio. GBL’s Clostridium fermentation platform converts a wide range of sustainable feedstocks into high performance green chemicals such as n-butanol, acetone, and through chemical synthesis, derivatives of butanol and acetone used by a growing global consumer and industrial products customer base. The platform combines advanced high productivity fermentation with superior-performing proprietary Clostridium microbial biocatalysts and synthetic chemistry to produce a pipeline of high value green chemicals with optimal performance in downstream formulations.
Green Biologics was named to the Global Cleantech 100 list of the top Cleantech companies in the world for 2014. The company was also #6 on the Hottest Small Companies in the Bioeconomy and #28 on the Hottest 30 list for Bio-based Chemicals and Materials for 2014.
Green Biologics is transforming the global chemicals market, providing its customers with products and technology that are more sustainable and higher value than petroleum-based alternatives. For more information, visit www.greenbiologics.com.
For Green Biologics
Timothy Staub – Global VP Business Development +1 804 368-6136 email@example.com
For Media Inquiries
Rob Adler – Vantage PR for Green Biologics 415-984-1970 x0104 firstname.lastname@example.org
- 8th August 2016
Silicon photonics pioneer looks to ease the data centre networking problem
- 1st August 2016
How green is my data centre?
- 29th July 2016
Next Generation Data Centre Networking
- 7th April 2016
Green Biologics Selects Nexeo Solutions as its U.S. Distribution Partner
- 3rd March 2016
Green Biologics Partners with Acme Hardesty
- 11th February 2016
Andrew Rickman to present ‘The disruptor’s view’ at TM&A Europe
- 29th January 2016
Green Biologics Named in the 2015 Global Cleantech 100
- 2nd December 2015
Green Biologics Starts Construction in Little Falls, MN
- 9th November 2015
The American Chemistry Council Approves Membership for Green Biologics
- 5th October 2015
The Future of the Data Center: Reinventing the Network
- 14th September 2015
Rockley Photonics demonstrates breakthrough technology
- 15th June 2015
ButaNext: Innovating to Create a More Effective Generation of Biofuels